Indication: Canine osteoarthritis and tendinopathy
Technology Platform: Canine adipose-derived allogeneic mesenchymal stem cells (MSCs)
CryoShot is our lead cell therapy technology for the treatment of canine osteoarthritis and other musculoskeletal disorders.
CryoShot is made from expanded allogeneic MSCs from canine adipose tissue. CryoShot works by reducing inflammation and promoting healing and repair in the damaged or diseased tissue.
CryoShot is currently being evaluated in a pre-pivotal trial assessing CryoShot as a treatment for canine osteoarthritis. For further information on this trial, please refer to our Trials page.
Points of difference
CryoShot is one of the new generation cell therapy treatments for osteoarthritis. CryoShot differs from other MSC therapies due to the considerable cost benefits of its manufacturing process. CryoShot manufacture has demonstrated the capability to produce commercial quantities of doses of cells from a single donor, which has many knock on benefits. Other traditional treatments for conditions such as osteoarthritis have been palliative pain medications. CryoShot is aimed at arresting the development and progression for osteoarthritis, as well as providing long-term pain release from a single intra-articular injection.
Next steps for CryoShot
In 2015 we entered into a collaboration and licence agreement with a major animal pharmaceutical company for the development and commercialisation of CryoShot. Upon completion of the pre-pivotal trial with the University of Pennsylvania, our partner has an option to exclusively licence the CryoShot technology, providing us with an upfront licence fee and other developmental milestone payments to be agreed upon at the time. The partner will be responsible for funding a pivotal trial with the US Food and Drug Administration (FDA) seeking registration of CryoShot in the US. The partner will have exclusive global rights for sales and marketing for canine applications. We will receive a royalty on all CryoShot sales.